6 results
To demonstrate that ofatumumab is superior to teriflunomide in reducing the frequency of confirmed relapses as evaluated by the annualized relapse rate (ARR) in patients with relapsing MS
Primary: To determine whether ofatumumab 3, 30 or 60 milligrams (mg) given subcutaneously (SQ), reduces the cumulative number of new T1 GdE brain lesions over a period of 12 weeks, as compared with placebo.Secondary: Cumulative number of new T1 GdE…
The primary objective is to evaluate progression free survival (PFS) of ofatumumab maintenance treatment versus no further treatment after remission induction in subjects with relapsed CLL.Secondary objectives are to evaluate clinical benefit,…
Primary: To evaluate the efficacy and safety of HuMax-CD20 in patients with B-cell Chronic Lymphocytic Leukemia (B-CLL) who have failed fludarabine and alemtuzumabSecondary: To determine the host immune response to HuMax-CD20To determine the…
Primary: To explore the effect of the H1-antagonist hydroxyzine 50 mg on motor response, attention and impulsivity, using a test battery and task manipulations. Secondary: To explore the effect of the H1-antagonist hydroxyzine 50 mg on…
Primary objective: To establish the safety of acquiring 2D and 3D hybrid images using IXSI in an interventional setting. Secondary objectives: To evaluate dosimetry of SPECT/CBCT acquired by IXSI. To image the (hemo-)dynamic processes influencing…